01:44 , Sep 11, 2015 |  BC Extra  |  Company News

Management tracks

PBM Express Scripts Holding Co. (NASDAQ:ESRX) said George Paz will retire as CEO, effective May 2016, while remaining non-executive chairman. Tim Wentworth, currently Express Scripts' president, will succeed Paz as CEO. Musculoskeletal play Radius Health...
02:34 , Oct 18, 2014 |  BC Extra  |  Company News

VC tracks

Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex Therapeutics...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Aldehyde dehydrogenase 2 family mitochondrial (ALDH2) Rodent studies suggest stimulating ALDH2 could help treat pain. In...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

Aldea Pharmaceuticals completes venture financing

Aldea Pharmaceuticals Inc., Redwood City, Calif.   Business: Cardiovascular   Date completed: 2014-08-25   Type: Venture financing   Raised: $24 million   Investors: RusnanoMedInvest; WuXi Corporate Venture Fund; Canaan Partners; Correlation Ventures   ...
00:36 , Aug 26, 2014 |  BC Extra  |  Financial News

Aldea closes $24 million B round

Aldea Pharmaceuticals Inc. (Redwood City, Calif.) closed a $24 million series B round led by new investor RusnanoMedInvest. New investor WuXi PharmaTech Corporate Venture also participated, along with all of Aldea's existing investors, including Canaan...
07:00 , Mar 13, 2014 |  BC Innovations  |  Strategy

Repairing reproducibility

Although the NIH is taking preliminary steps to improve the reliability of preclinical data, many researchers are not waiting for reproducibility guidelines and are taking up the mantle to raise standards at their own institutions. Francis...
08:00 , Dec 1, 2011 |  BC Innovations  |  Targets & Mechanisms

Taken to heart

A study by Stanford University School of Medicine researchers suggests a mitochondrial enzyme activator called Alda-1 could help decrease the risk of cardiac injury in patients receiving nitroglycerin for cardiac conditions.1 ALDEA Pharmaceuticals Inc. has...
08:00 , Nov 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Angina; myocardial infarction (MI); heart failure Aldehyde dehydrogenase 2 family mitochondrial (ALDH2)...